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Background: Non-inferiority (NI) trials in drug research are used to demonstrate that a new treatment is not less
effective than an active comparator. Since phase IV trials typically aim at informing a clinical decision, the value of a
phase IV non-inferiority trial hinges also on its clinical relevance. In such trials, clinical relevance would refer to the
added benefit claims of a specific drug, apart from efficacy, relative to its comparator drug in the trial.
Methods: In this study, we reviewed 41 phase IV trials and extracted information on whether the authors
mentioned any additional benefit beyond the NI (efficacy) claim of the drug and whether the additional benefit
was proven in the trial. We checked whether the additional claim was based on descriptions only or on formal
statistical analyses.
Results: Our results showed that 22 out of the 41 NI trials mentioned additional benefit of the test drug and most
of these claims were related to the safety profile. Of all the post-authorization NI trials that claimed additional
benefit, 10 out of 22 NI trials used formal statistical analyses to show additional benefit, and only one included a
sample size calculation for the additional benefit prior to the trial.
Conclusion: We conclude that there is room for improvement in terms of designing phase IV NI trials with added
benefit claims and in proving these additional claims.
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Non-inferiority (NI) trials in drug research are used to
demonstrate that a new treatment is not less effective than
an active (i.e. effective) comparator [1,2]. Thus, an NI trial,
which is mostly defined according to efficacy parameters,
indirectly shows that the new treatment is also effective.
However, the clinical significance of phase IV (i.e., “stud-
ies, other than routine surveillance, performed after drug
approval and related to the approved indication” [3]) NI
trials do not solely pertain to efficacy endpoints that were
already established in pre-authorization trials. Rather,
phase IV trials aim at “informing a decision” [4], or in
ethics, such a trial should disturb equipoise, i.e., the “state
of indifference or disagreement in the expert medical
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reproduction in any medium, provided the orprocedure” [5]. As such, in principle, all NI trials should
aim at specifying and demonstrating additional benefit
claims. NI trials performed after authorization have a
reinforced obligation to make additional claims, apart
from the primary (efficacy) endpoint, for the results of
such trials to be clinically relevant. Such additional claims
may relate to improved safety, but also optimization of
the method of administration, improved compliance, and
cost-effectiveness. Since the value of late stage NI trials
depends on these additional claims, appropriate study de-
sign and/or tests to demonstrate scientific validity of such
claims is truly important. Whether and how these claims
are scientifically justified in the NI trials currently per-
formed is, however, unknown.
In this study, we reviewed 41 published post-
authorization NI trials and determined whether these
trials reported benefit claims beyond clinical efficacy and
how these additional claims were supported or proven
in the trials.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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We included all post-authorization NI trial publications
among the 232 publications used for our earlier review
on NI trials [6]. In that review, we performed a search in
PUBMED on 5th February 2009, using the search terms,
“non-inferior*”, “noninferior*” or “active control” and
“equivalence”, in combination with the MeSH term
“humans” and “Randomized Controlled Trial” as publi-
cation type. This search resulted in 669 articles and,
based on pragmatic consideration rather than proper
sample size calculations, we randomly selected 300 for
our review. Subsequently, we excluded studies on bio-
equivalence, phase I studies, non-drugs trials, and arti-
cles that did not have full-text in English which resulted
in 227 articles that reported 232 NI trials.
We extracted the phase of the trial according to state-
ments in the publications or the referred clinical-trial
database (e.g. clinicaltrials.gov). We could only identify
the phase of 91 NI trials. Of the 91 trials, 15 were phase
IV trials. For the remaining 141 NI trials, we compared
the start date of the trial with the marketing approval
date of the studied drug. The marketing approval dates
were obtained from public domains. The first date of the
marketing approval anywhere in the world was consid-
ered as the date of the drug’s approval. If the trial started
later than the drug’s worldwide marketing approval date,
we considered it a phase IV trial. Of these 141 NI trials, we
identified 35 post-authorization trials. Hence, in total we
found 50 post-authorization trials. We excluded trials that
were aiming for the registration of a new indication (i.e.,
phase IIIB trials) by checking the aim of the trials stated in
the article and by double-checking in the public domain
via FDA and EMA websites. In total, we excluded nine
phase IIIB trials. In the end, we included 41 phase IV NI
trials in our analysis.
From each article, we extracted information on the type
of drug, type of trial initiator, number of trial subjects, type
of analysis (whether it is Intention-to-treat (ITT), Per-
protocol (PP) or both) and the conclusion of the trial. We
categorized the trials either as pharmaceutical-industry-
initiated or non-pharmaceutical-industry-initiated. A trial
is initiated by a pharmaceutical industry if besides the
sponsoring there was active involvement of the pharma-
ceutical industry in the trial process. This involvement in-
cluded any inputs of the pharmaceutical industry in
writing the trial protocol, trial monitoring, data analysis,
and reporting. If it is stated in the article that the pharma-
ceutical industry only gave unrestricted funding or grant,
without any other involvement, we classified the trial as
non-pharmaceutical industry-initiated.
Furthermore, we extracted information on whether the
authors mentioned any additional benefit beyond the NI
claim of the drug and whether the additional benefit was
substantiated in the trial via descriptions (e.g., via simpledistribution tables) or formal statistical analyses. We refer
to a formal statistical analysis as the existence of a priori
objective/hypothesis pertaining to the additional claim
which was accompanied by a sample size calculation and
(preferably) a data analysis plan. For example, if the author
mentioned that the additional benefit of the new drug was
its better safety profile, we evaluated whether the safety
data were presented descriptively, or if any sample size
calculation or any data analysis to establish statistical sig-
nificance was reported to test the difference in safety pro-
file between the two drugs. In addition, we extracted the
authors’ conclusion on the additional benefit.
GW and RB extracted all data and, in case of discrep-
ancies, reached consensus by discussion. All statistical
analyses were performed using SPSS 19 (SPSS Inc, USA;
www.spss.com).
Results
Description of the trials
Cardiovascular drugs and anti-infective drugs were the
most frequently studied drugs (22% for each; Table 1). The
majority of all the trials were initiated by the pharmaceu-
tical industry (61%). In 73% of the NI trials, the tested drugs
were concluded to be non-inferior to their comparators.
Additional benefit
Of the 41 NI trials, 22 (54%) mentioned additional bene-
fit of the test drug (Table 2). Among those 22 trials, the
additional benefit of “better safety profile” was most
often claimed (12 trials; 55%). Twelve trials (55%) stated
that the claimed additional benefits of the test drug were
proven in the current trial. In 10 trials (45%), formal
tests were used to explore statistical significance of the
claimed additional benefit, but only one performed a
sample size calculation for the claimed additional benefit
prior to the start of the trial [7].
Of the 25 NI trials with pharmaceutical industry in-
volvement, 14 (56%) mentioned additional benefit of
the test drug, while among the 12 non-pharmaceutical
industry initiated NI trials, five (42%) mentioned add-
itional benefit of the test drug (Table 3). Fourteen of the
25 NI trials with industry involvement claimed several
types of additional benefit; in five of these, statistical
testing was performed, while eight simply discussed the
additional benefit claims, and one did not discuss the add-
itional benefit claim at all. For the five non-pharmaceutical
industry initiated NI trials that claimed additional benefit,
“better safety profile” was most often claimed (four trials).
Four of the five latter trials used statistical tests to explore
the additional benefit claim.
Discussion
In our study of 41 phase IV NI trials, 54% reported
beneficial claims in addition to the NI claim and 55% of
Table 1 Characteristics of the NI trials
N (%)
(Unless stated otherwise)
I. Type of Drugs
Anti-infective 9 (22)
Cardiovascular system 9 (22)
Systemic hormonal preparations 5 (12)
Vaccines 5 (12)
Musculo-skeletal system 2 (5)
Nervous system 3 (7)
Antineoplastic 2 (5)
Others 6 (15)
II. Type of trial initiators
Non-pharmaceutical industry 12 (29)
Pharmaceutical industry 25 (61)
Not clear 4 (10)
III. Number of trial subjects
(median (interquartile range))
316 (196–629)
IV. Type of analysis
Both ITT and PP 19 (46)
ITT only 13 (32)
PP only 8 (20)_
Unclear 1 (2)





VI. Mentioned additional benefit 22 (54)
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authorization NI trials that claimed additional benefit,
45% performed tests to show statistical significance, and
only one included a pre-study sample size calculation for
the additional claim.
In the introduction, we stated that a phase IV trial
should aim at “informing a clinical decision.” We defined
“informing a decision” to refer to clinically relevantTable 2 Characteristics of additional benefit claims
Additional benefit N Presentation of additio
(N =22) Statistical test De
Convenient method of administration 1 0
Better safety profile 12 5
Better compliance 3 1
Less costly 1 0
Convenient method of administration
and better safety profile
5 4differences that would allow physicians to reasonably
choose one drug over another. As such, we have hinged
our definition on the obligation of the physician to
choose the best-suited therapy given the patient’s condi-
tion. However, these clinically relevant differences also
matter in the decision-making processes of the other
stakeholders such as the regulators, patient groups,
pharmaceutical industry, and third party payers. The im-
portance of these clinically relevant differences is illus-
trated by the emergence of relative effectiveness as an
important issue in the post-authorization stage, espe-
cially for third party payers such as the health insurance
agencies [4]. The European Commission’s High Level
Pharmaceutical Forum defines relative effectiveness as
“the extent to which an intervention does more good
than harm compared to one or more intervention alter-
natives for achieving the desired results when provided
under the usual circumstances of health care practice”
[4,8]. Ultimately, the aim of relative effectiveness assess-
ment is “to compare healthcare interventions in practice
in order to classify them according to their practical
therapeutic value” [8]. We can expect this issue to
sharpen as drug registration moves towards a “live li-
cense approach,” i.e., an approach where launch is lim-
ited, and the widening of the scope of the license
depends on post-authorization trial results [9]. In the lat-
ter case, relative effectiveness matters not only for the
payers but also for the regulators. Clearly, pharmaceut-
ical companies would need to demonstrate more than
ever the added value of a new drug, or in our terms, they
need to demonstrate clinically relevant differences.
Our results demonstrate that this need to establish
clinically relevant differences in post-authorization NI
trials through added benefit claims remains to be met.
The issue is emphasized by the fact that among those that
made additional benefit claims, only half used formal test-
ing to establish statistical significance, and the other half
merely presented their claims descriptively. It is question-
able if it is acceptable to base decisions/judgments of clin-
ical relevance if claims are not sufficiently supported by
evidence, such as those trials that only provide descrip-
tions of the additional benefit claims. Some may argue
that some additional benefits, such as the convenience ofnal benefit Conclusion on additional benefit
scriptively Proven Not proven Not explicitly discussed
0 0 0 1
7 7 3 2
2 3 0 0
1 0 0 1
1 2 2 1
Table 3 Additional benefit claims based on types of sponsor






















industry (n = 12)
7 (59) 0 4 (33) 0 0 0 1 (8)
Pharmaceutical
industry (n = 25)
11 (44) 1 (4) 8 (32) 1 (4) 1 (4) 3(12) 0
Not clear
(n = 4)





15 (50) 1 (3) 8 (27) 3 (10) 0 2 (7) 1 (3)
Superiority (n = 2) 0 0 2(100) 0 0 0 0
Inferiority (n = 6) 2 (33) 0 1(17) 0 1(17) 2 (33) 0
Other (n = 3) 2 (67) 0 1 (33) 0 0 0 0
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intravenous route, may be obvious; hence, there is no need
for evidentiary support. However, even for such claims,
evidence is needed, as patients’ preferences may be differ-
ent. Oral route might be more convenient in the physi-
cian’s perspective, but for the patient, the shape or the
taste of the pill may be real issues, and therefore, the intra-
venous route could be better.
Apart from these scientific and regulatory issues with
post-authorization NI trials without added benefit
claims, or those with added benefit claims but without
(or with questionable) scientific evidence, there is also
an issue with the ethical justification of these trials. It is
ethical for a trial to begin with the assumption of equi-
poise with the aim of disturbing it. Equipoise justifies
the inclusion of patient-participants since the state of
equipoise retains the possibility of a medically endors-
able therapeutic benefit. Disturbing equipoise unambigu-
ously establishes the value of an intervention, and hence,
a trial that aims to disturb equipoise also aims to “im-
prove preventive, diagnostic and therapeutic interven-
tions (methods, procedures and treatments)” [10]. A trial
that does not show that intervention A is in some way
better than intervention B does not contribute to the im-
provement of therapeutic interventions. Hence, a phase
IV NI trial that does not aim to assess benefit claims of
the new drug does not disturb nor is it expected to dis-
turb equipoise precisely because its goal is simply to
show that A is not worse than B, and not that A is in
some way better than B, a goal that does not even partly
resolve the state of indifference and/or disagreement in
the expert medical community. As such, a phase IV NI
trial without added benefit claims may have ethical justi-
fication issues. In our study, only half of the NI trials
claimed such additional benefits.Of the 25 pharmaceutical industry-initiated trials,
about half (56%) claimed multiple additional benefits.
The variety of additional benefit claims made by the in-
dustry seems encouraging, as this may be a sign of how
the industry tries to resolve the relative effectiveness
obstacle. However, the absence of statistical testing and
the reliance on mere descriptions of the alleged benefit
in majority of the pharmaceutical industry initiated post-
authorization NI trials bring us back to the evidence-
problem we discussed earlier.
Lastly, the limited (in terms of number and variety)
additional benefit claims in NI trials from independent
investigators and in government initiated trials may be
an indication that non-industry bodies are still generally
more concerned about the narrower concepts of safety
and efficacy (as opposed to the wider benefit-risk assess-
ment, which includes factors beyond safety and efficacy
[11]). This is understandable and useful for regulatory
purposes; but this situation does not help ease the im-
pending relative efficacy and live license hurdles.
Based on the foregoing discussions, it is clear at this
point that post-authorization NI trials need to be
designed such that potentially, the resulting data are
capable of disturbing equipoise and hence address issues
such as relative effectiveness. This may be enhanced by
closer and earlier collaboration between stakeholders
[12,13]. In addition, in a previous article, we pointed out
that NI trials may be designed in a manner that simul-
taneously shows the NI objective “with regard to drug
efficacy and the objective of establishing superiority of
the additional advantages of a drug over its active com-
parator.” [14] This may be a viable direction to follow if
we are to revise the methodology of phase IV NI trials.
Our small sample size is a limitation of this study. In
addition, clinical relevance cannot be directly investigated
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Another limitation will be the fact that our current ana-
lysis was part of previous analysis where we had randomly
selected 300 articles from 669 articles found in Pubmed
on the 5th February 2009. As expected, since that date,
there were more articles on NI trials that were published
and indexed in Pubmed. Thus, we missed recently pub-
lished Phase IV NI trials. However, we do not believe the
main message of our article, i.e., the importance of show-
ing additional benefits in Phase IV NI trials, will differ
much with addition of those new articles in our analysis.
There may be concerns that phase IV trials could be
described as superiority trials in PUBMED and the (subor-
dinate) non-inferiority objective may not have been men-
tioned in the abstract. However, a trial is referred to as
superiority or non-inferiority based on its primary objec-
tive and not on its secondary/subordinate objective.
Hence, we believe we did not miss any phase IV NI trial
given our search strategy. To include trials that are not
explicitly stated as NI trials, in our opinion, would be ex-
tremely difficult. Our analysis was done based on pub-
lished reports in PUBMED. We did not include trials
databases, such as the clinicaltrials.gov, since data in-
cluded in these databases are not suitable for our in-depth
analysis (for example, data on NI margin and how it was
determined are missing from such a database).
Conclusion
Our study clearly shows that post-marketing NI trials
vary considerably in their aims and claims. Importantly,
only about half of the trials claimed additional benefit.
Consequently, post-authorization NI trials need to be
more robust, i.e., these trials must produce information
that is directly useful to the clinical setting. Moreover,
these trials must show scientific validity if they are to
claim any additional value that physicians can bank on.
Hence, there is room for improvement in terms of de-
signing phase IV NI trials with additional benefit claims
and in proving these additional claims.
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